US Bancorp DE Has $12.57 Million Holdings in AstraZeneca PLC (NASDAQ:AZN)

US Bancorp DE increased its holdings in AstraZeneca PLC (NASDAQ:AZNFree Report) by 20.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 186,629 shares of the company’s stock after acquiring an additional 31,252 shares during the period. US Bancorp DE’s holdings in AstraZeneca were worth $12,570,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Wellington Management Group LLP raised its holdings in shares of AstraZeneca by 0.7% in the 3rd quarter. Wellington Management Group LLP now owns 49,492,814 shares of the company’s stock worth $3,351,653,000 after acquiring an additional 358,399 shares during the last quarter. Sanders Capital LLC acquired a new stake in shares of AstraZeneca in the 3rd quarter worth about $715,198,000. Fisher Asset Management LLC raised its holdings in shares of AstraZeneca by 2.5% in the 4th quarter. Fisher Asset Management LLC now owns 9,404,023 shares of the company’s stock worth $633,361,000 after acquiring an additional 233,015 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in shares of AstraZeneca by 5.0% in the 3rd quarter. Ameriprise Financial Inc. now owns 4,242,708 shares of the company’s stock worth $287,294,000 after acquiring an additional 201,104 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of AstraZeneca by 2.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,971,501 shares of the company’s stock worth $267,469,000 after acquiring an additional 96,201 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on AZN. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, April 16th. BMO Capital Markets increased their price objective on shares of AstraZeneca from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Friday, April 26th. Three research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $82.00.

View Our Latest Report on AstraZeneca

AstraZeneca Trading Up 0.5 %

NASDAQ:AZN opened at $78.54 on Monday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.70 and a current ratio of 0.89. The firm has a market cap of $243.51 billion, a price-to-earnings ratio of 38.50, a price-to-earnings-growth ratio of 1.41 and a beta of 0.47. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $79.36. The firm has a 50-day moving average price of $71.80 and a two-hundred day moving average price of $67.80.

AstraZeneca (NASDAQ:AZNGet Free Report) last posted its quarterly earnings data on Thursday, April 25th. The company reported $1.03 EPS for the quarter, beating the consensus estimate of $0.95 by $0.08. AstraZeneca had a net margin of 13.30% and a return on equity of 30.42%. The firm had revenue of $12.68 billion during the quarter, compared to analyst estimates of $11.92 billion. On average, equities analysts expect that AstraZeneca PLC will post 4.04 earnings per share for the current fiscal year.

About AstraZeneca

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Read More

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZNFree Report).

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.